NCT03387917: TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors

NCT03387917
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Known symptomatic CNS or leptomeningeal metastases
https://ClinicalTrials.gov/show/NCT03387917

Comments are closed.

Up ↑